Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Genfit SA ( (GNFT) ) has shared an update.
On January 29, 2025, GENFIT announced its provisional financial calendar for 2025, outlining key dates for publishing financial results and holding its Annual Shareholders Meeting. The financial updates and corporate events scheduled for the year include the publication of revenue and cash positions, full-year financial statements, and the half-year financial review. This announcement provides stakeholders with a timeline of GENFIT’s financial disclosures, reflecting the company’s commitment to transparency and regulatory compliance. The release of these financial documents and meetings is crucial for investors and other stakeholders to assess GENFIT’s financial health and strategic direction.
More about Genfit SA
GENFIT is a late-stage biopharmaceutical company focused on treating rare and life-threatening liver diseases with unmet medical needs. The company has a strong history in liver disease research and development, boasting a diverse and expanding R&D portfolio. GENFIT’s primary focus is on Acute-on-Chronic Liver Failure (ACLF) with several assets in development targeting various liver-related conditions. The company is also involved in diagnostics and has successfully gained regulatory approvals for its products in major markets. GENFIT is headquartered in Lille, France, and operates in Europe and the United States.
YTD Price Performance: 0.26%
Average Trading Volume: 7,783
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $179.7M
Find detailed analytics on GNFT stock on TipRanks’ Stock Analysis page.
